

Cyient, Agappe take diagnostic capabilities to rural India

10 September 2020 | News

Cyient will manufacture certain key components of Mispa Count X at its ISO 13485-certified, state-of-art manufacturing facilities in India



Cyient, a global engineering and digital technology solutions company, has announced that it has entered into a manufacturing partnership with Cochin based Agappe to bring to market Count X.

The Mispa Count X is an indigenously designed and developed three-part hematology analyzer by Agappe, that will make India self-reliant in hematology and enable the setup of well-equipped labs in remote and rural locations across India. Cyient will manufacture certain key components of Mispa Count X at its ISO 13485-certified, state-of-art manufacturing facilities in India.

Rajendra Velagapudi, Senior Vice President and CEO, Cyient DLM, commented, "We are proud to support the vision of an Atmanirbhar Bharat (self-reliant India) in the healthcare sector. It is a matter of immense pride that with Agappe's new hematology product, even rural India and other remote locations of the country will have access to the best of diagnostic capabilities."

Hyderabad based Cyient's world-class facilities, project management, sourcing, supply chain management, production processes, buoyed by investments in the latest technologies as well as expertise in the delivery of quality products, make it a preferred manufacturing partner for aerospace, defense, medical, and industrial customers globally.

Dr. Satheesh Kumar CS, Senior Vice President, Agappe, said, "This partnership will enable Agappe to deliver high-quality, affordable, 100% made-in-India products by taking advantage of Cyient's ultra-modern manufacturing facilities to manufacture some of the key components of Mispa Count X so as to reduce time-to-market and lower operating costs. We are eager to get started with full-scale production in our manufacturing facility at Cochin and fulfill customer orders on time."